SCHEMBL7202911

SCHEMBL7202911

Cc1c(S(=O)(=O)Nc2ccc3c(c2)N(CCN(C)C)CC3)sc2ccc(Cl)cc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 14/20 0.63
HTR1A P08908 4/20 0.59
HTR1D P28221 4/20 0.59
HTR1B P28222 4/20 0.59
HTR7 P34969 4/20 0.59
HTR2A P28223 3/20 0.59
DRD2 P14416 3/20 0.59
HTR2C P28335 3/20 0.59
ADRA1B P35368 3/20 0.59
DRD3 P35462 3/20 0.59
HTR4 Q13639 3/20 0.59
HTR2B P41595 2/20 0.59
HTR1E P28566 1/20 0.59
HTR1F P30939 1/20 0.59
NPSR1 Q6W5P4 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
PFKFB3 Q16875 2/20 0.55
PFKFB4 Q16877 2/20 0.55
DRD1 P21728 1/20 0.54
DRD4 P21917 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10239970 0.79 HTR6 (0.63) HTR6HTR1AHTR1DHTR1BHTR7
Hydrochloric Acid SCHEMBL3153634 0.78 HTR6 (0.62) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL6981823 0.77 HTR6 (0.80) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL6972216 0.77 HTR6 (0.80) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL3144856 0.77 HTR6 (0.87) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL3157138 0.77 HTR6 (0.72) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL3154082 0.77 HTR6 (1.00) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL2905817 0.77 HTR6 (0.75) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL3148659 0.76 HTR6 (0.73) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL6980956 0.76 HTR6 (0.77) HTR6HTR1AHTR1DHTR1BHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0946539-A1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 1999-10-06 EP claimed
WO-1998027081-A1 SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 1998-06-25 WO claimed
US-20090005417-A1 Substituted Indazolyl Sulfonamide and 2,3-Dihydro-Indolyl Sulfonamide Compounds, their Preparation and Use in Medicaments LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2009-01-01 US disclosed
US-20090005417-A1 Substituted Indazolyl Sulfonamide and 2,3-Dihydro-Indolyl Sulfonamide Compounds, their Preparation and Use in Medicaments LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2009-01-01 US disclosed
US-6599904-B2 5-HT6 receptor antagonists are believed to be of potential use in the treatment of certain CNS disorders; cognitive memory enhancement SMITHKLINE BEECHAM P.L.C. (GB) 2003-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005417-A1 Substituted Indazolyl Sulfonamide and 2,3-Dihydro-Indolyl Sulfonamide Compounds, their Preparation and Use in Medicaments HTR6, TPH2, HTR5A HTR6 1/4885HTR1A 11/4885HTR1D 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.